Common name |
B-hHER2 MC38 | Catalog number | 310701 |
Aliases |
ERBB2, CD340, HER-2, HER-2/neu, HER2, MLN 19, NEU, NGL, TKR1, VSCN2, erb-b2 receptor tyrosine kinase 2 |
Disease | Colon carcinoma |
Organism |
Mouse |
Strain | C57BL/6 |
Tissue types | Colon | Tissue | Colon |
Description
The mouse Erbb2 gene was replaced by human ERBB2 coding sequence in B-hHER2 MC38 cells. Human ERBB2 is highly expressed on the surface of B-hHER2 MC38 cells.
Application
Targeting strategy
Gene targeting strategy for B-hHER2 MC38 cells.The exogenous CAG promoter and human ERBB2 coding sequence was inserted to replace part of murine exon 2 and all of exons 3-7. The insertion disrupts the endogenous murine Erbb2 gene, resulting in a non-functional transcript.
Protein expression analysis
HER2 expression analysis in B-hHER2 MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-hHER2 MC38 cultures were stained with species-specific anti-HER2 antibody. Mouse HER2 was detectable in wild-type MC38 cells. Human HER2 was detected on the surface of B-hHER2 MC38 cells but not wild-type MC38 cells. The 2-B06 clone of B-hHER2 MC38 cells was used for in vivo tumor growth assays.
Tumor growth curve & Body weight changes
Protein expression analysis of tumor cells
B-hHER2 MC38 cells were subcutaneously transplanted into C57BL/6 mice (n=5) . At the end of the experiment, tumor cells were harvested and assessed for human HER2 expression by flow cytometry. As shown, human HER2 was highly expressed on the surface of tumor cells. Therefore, B-hHER2 MC38 cells can be used for in vivo efficacy studies of HER2 therapeutics.
Tumor growth curve & Body weight changes
B-hHER2 MC38 cells were subcutaneously transplanted into heterozygous B-hCD3E/hHER2 mice (female, 7-week-old, n=5), and on 31 days post inoculation, tumor cells were harvested and assessed for human HER2 expression by flow cytometry. As shown, human HER2 was highly expressed on the surface of tumor cells. Therefore, B-hHER2 MC38 cells can be used for in vivo efficacy studies of HER2 therapeutics.
B-hHER2 MC38 cells were subcutaneously transplanted into B-hCD3E mice (n=5), and on 35 days post inoculation, tumor cells were harvested and assessed for human HER2 expression by flow cytometry. As shown, human HER2 was highly expressed on the surface of tumor cells. Therefore, B-hHER2 MC38 cells can be used for in vivo efficacy studies of HER2 therapeutics.
Tumor growth curve & Body weight changes